Aptar Pharma Launches Integrated System-Level Framework to Support Injectable Drug Development

About this update from Aptargroup, Inc.

Combines partner collaboration, system-level testing and performance data packages to support earlier development decisions and help address evolving USP <382> expectations CRYSTAL LAKE, Ill., July 17, 2026 --( BUSINESS WIRE )--Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced a collaborative system-level framework for injectable drug delivery systems. Building on more than a decade of supporting pharmaceutical customers in respiratory and ophthalmic drug development, Aptar Pharma will work with partners to develop data packages that combine integrated system-level testing and performance data for injectable therapies. Designed to provide earlier insight into assembled-system performance, these data packages help customers make more informed development decisions, better manage risk across development programs and support the delivery of safe and effective therapies to patients. As biologics, sensitive vaccines and combination products evolve, pharmaceutical companies are seeking earlier insight into assembled-system performance to support development decisions and address the expectations of USP <382>. Aptar Pharma's Injectables division is built on more than 60 years of experience in elastomeric components for injectable drug delivery systems. By developing elastomeric solutions for these systems and working with leading partners across the injectable value chain, including pre-filled syringe (PFS) manufacturers, Aptar Pharma brings together partner collaboration, component expertise and integrated data to support customers throughout development. The current focus is on partner PFS platforms incorporating Aptar Pharma rigid needle shields (RNS) and PremiumCoat® elastomeric plungers for sensitive drug formulations, including highly viscous biologics. Container closure systems are often assessed component by component, requiring co-ordination across multiple suppliers and issue resolution as development progresses. This can make it challenging for customers to establish a complete view of assembled-system performance early in development. Aptar Pharma's approach helps address this by supporting earlier system-level evaluations with partners and generating data on interactions between critical system components, in line with USP <382> principles. Through its partner network, Aptar Pharma is developing data packages covering functional performance, container closure integrity testing (CCIT), sealing performance and component interactions to help customers:

View stock analysis, news, and events for Aptargroup, Inc.